A Multicenter Phase II Study of Modified FOLFIRINOX for First-Line Treatment for Advanced Urachal Cancer (ULTIMA; KCSG GU20-03). Park I, Lee JL, Yoon S, Shin SJ, et al. Cancer Res Treat 2026;58:284-291.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Park I, Lee JL, Yoon S, Shin SJ, et al. A Multicenter Phase II Study of Modified FOLFIRINOX for First-Line Treatment for Advanced Urachal Cancer (ULTIMA; KCSG GU20-03). Cancer Res Treat 2026;58:284-291.
PMID: 39961593